BeiGene Ltd. (BGNE) Scheduled to Post Quarterly Earnings on Friday
BeiGene Ltd. (NASDAQ:BGNE) will be posting its quarterly earnings results on Friday, October 7th. Individual that wish to listen to the company’s earnings conference call can do so using this link.
BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $2.08 million. BeiGene’s quarterly revenue was down 71.4% on a year-over-year basis. On average, analysts expect BeiGene to post $-3.38 EPS for the current fiscal year and $-3.38 EPS for the next fiscal year.
BeiGene Ltd. (NASDAQ:BGNE) opened at 31.68 on Thursday. The stock’s 50 day moving average is $30.17 and its 200-day moving average is $29.19. BeiGene Ltd. has a 1-year low of $22.51 and a 1-year high of $35.60. The firm’s market cap is $1.04 billion.
In related news, Director Donald W. Glazer sold 41,463 shares of the stock in a transaction on Wednesday, September 28th. The stock was sold at an average price of $30.66, for a total value of $1,271,255.58. Following the completion of the transaction, the director now owns 4,881,997 shares in the company, valued at approximately $149,682,028.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald W. Glazer sold 67,252 shares of the stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $31.42, for a total value of $2,113,057.84. Following the completion of the transaction, the director now owns 4,882,000 shares of the company’s stock, valued at approximately $153,392,440. The disclosure for this sale can be found here.
Several institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its position in BeiGene by 34.0% in the second quarter. FMR LLC now owns 2,300,337 shares of the company’s stock worth $68,550,000 after buying an additional 583,277 shares during the period. Vident Investment Advisory LLC acquired a new stake in shares of BeiGene during the second quarter worth approximately $678,000. BlackRock Institutional Trust Company N.A. raised its stake in shares of BeiGene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock worth $191,000 after buying an additional 2,589 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of BeiGene by 3,410.1% in the second quarter. BlackRock Inc. now owns 3,826 shares of the company’s stock worth $114,000 after buying an additional 3,717 shares during the last quarter. Institutional investors and hedge funds own 26.26% of the company’s stock.
BGNE has been the topic of a number of research analyst reports. Zacks Investment Research raised BeiGene from a “sell” rating to a “hold” rating in a report on Monday, September 19th. Maxim Group initiated coverage on BeiGene in a report on Wednesday, September 21st. They set a “buy” rating and a $41.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. BeiGene has a consensus rating of “Buy” and an average target price of $40.00.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.